Title: USE OF KPV TRIPEPTIDE FOR DERMATOLOGICAL DISORDERS

Abstract: The present invention is directed to a prevention and treatment for dermatological disorders. One aspect of this invention involves a dermatological treatment comprising one or more polypeptides with an amino acid sequence including KPV (SEQ. ID.NO. 1), MEHRWGKPV (SEQ. ID. NO. 2), HFRWGKPV (SEQ. ID. NO. 3), OS SYMREHRWGKPV (SEQ. ID. NO. 4) for the treatment and prevention of dermatological disorders. The polypeptides are at a level to effectively treat the cutaneous inflammation and are carried by a carrier. The one or more polypeptides can also be a dimer formed from any of the amino acid sequences above.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00
US CL : 514/14, 15, 16, 18; 530/306, 312, 326, 327

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 14, 15, 16, 18; 530/300, 306, 312, 326, 327, 328, 331

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 88/00833 A2 (LIPTON et al) 11 February 1988 (11.02.1988), see abstract; page 5, lines 5-13; page 5, lines 32-36; page 10, lines 23-29; page 11, lines 1-6; page 21, lines 11-25, see entire document.</td>
<td>1-2, 5, 7-11, 14, 16-21, 24, 26-30, 33, 35-38</td>
</tr>
<tr>
<td>X,P</td>
<td>US 6,385,929 B1 (MAHE et al.) 19 March 2002 (19.03.2002), column 3, lines 43-52, column 4, lines 1-14, see abstract, see entire document.</td>
<td>3-4, 6, 12-13, 15, 22-23, 25, 31-32, 34</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

Special categories of cited documents:

*A* document defining the general state of the art which is not considered to be of particular relevance

*B* earlier application or patent published on or after the international filing date

*L* document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)

*C* document referring to an oral disclosure, use, exhibition or other means

*P* document published prior to the international filing date but later than the priority date claimed

*"I*" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

*"X*" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

*"Y*" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

*"&*" document member of the same patent family

Date of the actual completion of the international search: 18 June 2002 (18.06.2002)

Date of mailing of the international search report: 18 SEP 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. 703/305-3230

Authorized officer: B. Della Chiesa

Telephone No. 703/308-0196

Form PCT/ISA/210 (second sheet) (July 1998)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X,P</td>
<td>US 6,337,315 B1 (MAHE et al.) 08 January 2002 (08.01.2002), see abstract; column 6, lines 50-67; column 7, lines 6-44, see entire document.</td>
<td>1, 5, 7, 8, 9, 10, 14, 16, 17, 18, 19, 20, 24, 26, 27, 28, 29, 33, 35, 36, 37, 38</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2, 11, 21, 30</td>
</tr>
<tr>
<td>Y,P</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Continuation of B. FIELDS SEARCHED Item 3:
BIOSIS LIFESCI MEDLINE
search terms: KPV, Lys-Pro-Val, glucocorticoid, anti-inflammatory, non-steroidal, aspirin, pharmaceutical, ibuprofen, fenoprofen, naproxen, ointment, indomethacin, tolmetin, skin dermis epidermis, alpha-msh